Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

Christopher G. Hayes net worth and biography

Christopher Hayes Biography and Net Worth

Insider of Verrica Pharmaceuticals

Mr. Hayes has served as Verrica Pharmaceuticals’ General Counsel since September 2018, and as Chief Legal Officer since February 2020. He is also our Chief Compliance Officer and Corporate Secretary. With over 30 years of wide-ranging, substantive business and legal experience, Mr. Hayes provides critical legal guidance and effective solutions to drive Verrica on the right path forward, creating value, mitigating risk, and optimizing capabilities for all stakeholders. His extensive legal knowledge spans corporate and securities law and litigation, commercial transactions, contract administration, antitrust law and complex litigation, corporate development and governance, and labor and employment law. Mr. Hayes received a BA in Economics from Villanova University and a JD from The Catholic University of America, Columbus School of Law.

What is Christopher G. Hayes' net worth?: The estimated net worth of Christopher G. Hayes is at least $571,836.50 as of July 24th, 2023. Mr. Hayes owns 81,925 shares of Verrica Pharmaceuticals stock worth more than $571,837 as of April 20th. This net worth approximation does not reflect any other investments that Mr. Hayes may own. Learn More about Christopher G. Hayes' net worth.
How old is Christopher G. Hayes?: Mr. Hayes is currently 60 years old. There are 2 older executives and no younger executives at Verrica Pharmaceuticals. Learn More on Christopher G. Hayes' age.
How do I contact Christopher G. Hayes?: The corporate mailing address for Mr. Hayes and other Verrica Pharmaceuticals executives is 10 NORTH HIGH STREET SUITE 200, WEST CHESTER PA, 19380. Verrica Pharmaceuticals can also be reached via phone at (434) 453-3300 and via email at [email protected]. Learn More on Christopher G. Hayes' contact information.
Has Christopher G. Hayes been buying or selling shares of Verrica Pharmaceuticals?: Christopher G. Hayes has not been actively trading shares of Verrica Pharmaceuticals during the last quarter. Most recently, Christopher G. Hayes sold 33,789 shares of the business's stock in a transaction on Monday, July 24th. The shares were sold at an average price of $4.83, for a transaction totalling $163,200.87. Following the completion of the sale, the insider now directly owns 81,925 shares of the company's stock, valued at $395,697.75. Learn More on Christopher G. Hayes' trading history.
Who are Verrica Pharmaceuticals' active insiders?: Verrica Pharmaceuticals' insider roster includes Matt Davidson (Major Shareholder), A. Davis (CFO), Christopher Hayes (Insider), Paul Manning (Director), and Ted White (CEO). Learn More on Verrica Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Verrica Pharmaceuticals?: During the last year, Verrica Pharmaceuticals insiders bought shares 6 times. They purchased a total of 1,537,691 shares worth more than $8,942,546.19. During the last year, insiders at the sold shares 3 times. They sold a total of 106,046 shares worth more than $471,200.18. The most recent insider tranaction occured on December, 28th when Major Shareholder Perceptive Advisors Llc bought 126,116 shares worth more than $892,901.28. Insiders at Verrica Pharmaceuticals own 41.5% of the company. Learn More about insider trades at Verrica Pharmaceuticals.
Information on this page was last updated on 12/28/2023.

Christopher G. Hayes Insider Trading History at Verrica Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/24/2023	Sell	33,789	$4.83	$163,200.87	81,925
7/11/2022	Buy	7,500	$3.40	$25,500.00	15,714
7/5/2022	Buy	5,714	$2.10	$11,999.40	8,214
6/4/2021	Buy	2,500	$9.79	$24,475.00	2,500

Christopher G. Hayes Buying and Selling Activity at Verrica Pharmaceuticals

Verrica Pharmaceuticals Company Overview

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

Today's Range

Now: $6.98

$6.78

$7.01

50 Day Range

MA: $5.70

$4.74

$7.19

2 Week Range

Now: $6.98

$2.86

$7.76

Volume

125,729 shs

Average Volume

179,073 shs

Market Capitalization

$296.09 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.88

Secret Bull Market Starts in This Unusual Sector

From Altimetry | Ad